Arca
Skip to content
Tools
Tools

ROS1, SDC4: ROS1-SDC4

Chimeric protein in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ROS1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Repotrectinib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        RepotrectinibApprovedBristol-Myers SquibbSmall moleculeInhibitorROS1-SDC4 inhibitor8

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanRepotrectinib—RecruitingBristol-Myers SquibbAug 10, 2026
        Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionRepotrectinib—Not yet recruitingBristol-Myers SquibbMay 20, 2026
        Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRepotrectinibPhase 2RecruitingCentre Hospitalier Intercommunal de Toulon La Seyne sur MerAug 13, 2024
        Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRepotrectinibPhase 2RecruitingMedSIRMar 18, 2024
        A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)RepotrectinibPhase 3Active, not recruitingBristol-Myers SquibbNov 20, 2023
        A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRepotrectinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer CenterAug 13, 2021
        A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Sep 19, 2019
        A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.Mar 28, 2017

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5303568, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.